HC Wainwright Reaffirms Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)
HC Wainwright restated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $66.00 price target on the stock. Several other brokerages have also commented on MIRM. SVB Leerink lowered their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 […]
More Stories
Golden Minerals (NYSE:AUMN) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Golden Minerals (NYSE:AUMN – Free Report) in a report released on Thursday. The brokerage...
Eastman Chemical (NYSE:EMN) Upgraded by StockNews.com to “Buy” Rating
StockNews.com upgraded shares of Eastman Chemical (NYSE:EMN – Free Report) from a hold rating to a buy rating in a...
Apple Hospitality REIT (NYSE:APLE) Lowered to Sell Rating by StockNews.com
StockNews.com downgraded shares of Apple Hospitality REIT (NYSE:APLE – Free Report) from a hold rating to a sell rating in...
Head-To-Head Survey: ENN Energy (OTCMKTS:XNGSY) & Centuri (NYSE:CTRI)
ENN Energy (OTCMKTS:XNGSY – Get Free Report) and Centuri (NYSE:CTRI – Get Free Report) are both utilities companies, but which...
Grove Reaches 24 Hour Volume of $79,346.46 (GVR)
Grove (GVR) traded 3% lower against the U.S. dollar during the 24 hour period ending at 13:00 PM ET on...
Tesla, Inc. (NASDAQ:TSLA) Position Raised by CIBC Asset Management Inc
CIBC Asset Management Inc raised its position in shares of Tesla, Inc. (NASDAQ:TSLA – Free Report) by 6.2% in the...